Evaluation of the Effectiveness of Vaccination of Russian Railways employees

Relevance. The effectiveness of vaccination of the working population against COVID-19 in the Russian background has not been studied enough.

Aim. To evaluate the effectiveness of vaccination of the working population with Gam-COVID-Vak (Sputnik V) in the Russian Railways as an example.

Materials & Methods.The effectiveness of vaccination with Sputnik V among employees of Russian Railways in the period from January 21 to November 31, 2021 was performed with the Cox regression method.

Results. The effectiveness of Sputnik V against COVID-19 infection with was 97.8% (95% CI 97.8–97.9%) for two doses, 91.9% (95% CI 91.6–92.2%) for a single dose, and 97.9% (95% CI 97.6–98.1%) for revaccination, all after socio-demographic factors adjusted. The effectiveness of vaccination against COVID-19 with hospitalization was 97.5% for two doses of Sputnik V (95% CI 97.1–97.9%), 86.1% (95% CI 83.7–88.1%) for a single dose, and 98.2% (95% CI 96.3–99.2%) for revaccination. The effectiveness against lethal COVID-19 was 95.2% (95% CI 93.1–96.6%) for two doses of Sputnik V and 94.8% (95% CI 89–97.6%) for one dose. The high efficiency of vaccination could be associated with a fairly young age composition of the employees of the Russian Railways.

Conclusions. The study showed the high effectiveness of vaccination with Sputnik V against COVID-19 among the working population.

1. Logunov DY, Dolzhikova IV, Shcheblyakov DV, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021;397:671–81. doi:10.1016/S0140-6736(21)00234-8

2. González S, Olszevicki S, Salazar M, et al. Effectiveness of the first component of Gam-COVID-Vac (Sputnik V) on reduction of SARS-CoV-2 confirmed infections, hospitalisations and mortality in patients aged 60-79: a retrospective cohort study in Argentina. EClinicalMedicine 2021; 40: 101126. doi:10.1016/j.eclinm.2021.101126

3. Rearte A, Castelli JM, Rearte R, et al. Effectiveness of rAd26-rAd5, ChAdOx1 nCoV-19, and BBIBP-CorV vaccines for risk of infection with SARS-CoV-2 and death due to COVID-19 in people older than 60 years in Argentina: a test-negative, case-control, and retrospective longitudinal study. Lancet 2022; 399: 1254–64. doi:0.1016/S0140-6736(22)00011-3

4. Vokó Z, Kiss Z, Surján G, et al. Nationwide effectiveness of five SARS-CoV-2 vaccines in Hungary-the HUN-VE study. Clin Microbiol Infect 2022;28:398–404. doi:10.1016/j.cmi.2021.11.011

5. Petrović V, Vuković V, Patić A, et al. Immunogenicity of BNT162b2, BBIBP-CorV and Gam-COVID-Vac vaccines and immunity after natural SARS-CoV-2 infection-A comparative study from Novi Sad, Serbia. PLoS One 2022; 17: e0263468. doi:10.1371/journal.pone.0263468

6. Matveeva O, Ershov A. Retrospective Cohort Study of the Effectiveness of the Sputnik V and EpiVacCorona Vaccines against the SARS-CoV-2 Delta Variant in Moscow (June–July 2021). Vaccines. 2022; 10: 984. doi:10.3390/vaccines10070984

7. Ryzhikov AB, Ryzhikov ЕА, Bogryantseva MP, et al. A single blind, placebo-controlled randomized study of the safety, reactogenicity and immunogenicity of the ‘EpiVacCorona’ Vaccine for the prevention of COVID-19, in volunteers aged 18–60 years (phase I–II). Infektsiia Immun. 2021; 11: 283–96. doi:10.15789/2220-7619-ASB-1699

8. Kozlovskaya LI, Piniaeva AN, Ignatyev GM, et al. Long-term humoral immunogenicity, safety and protective efficacy of inactivated vaccine against COVID-19 (CoviVac) in preclinical studies. Emerg Microbes Infect. 2021; 10: 1790–806. doi:10.1080/22221751.2021.1971569

9. Bagrov DV, Glukhov GS, Moiseenko AV, et al. Structural characterization of β-propiolactone inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) particles. Microsc Res Tech. 2022; 85: 562–9. doi:10.1002/jemt.23931

10. Ishmukhametov AA, Siniugina AA, Yagovkina NV, et al. Safety and immunogenicity of inactivated whole virion vaccine CoviVac against COVID-19: a multicenter, randomized, double-blind, placebocontrolled phase I/II clinical trial. bioRxiv. 2022; published online Feb 9. doi:10.1101/2022.02.08.22270658

11. Korang SK, von Rohden E, Veroniki AA, et al. Vaccines to prevent COVID-19: A living systematic review with Trial Sequential Analysis and network meta-analysis of randomized clinical trials. PLoS One. 2022; 17: e0260733. doi:10.1186/s13643-020-01516-1

12. Shah S, Gui H, Chua PEY, et al. Factors associated with COVID-19 vaccination intent in Singapore, Australia and Hong Kong. Vaccine. 2022; 40: 2949–59. doi:10.1016/j.vaccine.2022.03.062

13. Falahi S, Kenarkoohi A. Host factors and vaccine efficacy: Implications for COVID-19 vaccines. J Med Virol. 2022; 94: 1330–5. doi:10.1002/jmv.27485

14. Su Z, Cheshmehzangi A, McDonnell D, et al. Gender inequality and health disparity amid COVID-19. Nurs Outlook. 2022; 70: 89–95. doi:10.1016/j.outlook.2021.08.004

15. Zhidkova EA, Gutor EM, Vilk MF, et al. The study of attitudes towards health and a healthy lifestyle among employees of the railway industry. Problems of social hygiene, health care and the history of medicine. 2021; 29:1350–7. (In Russ). doi:10.32687/0869-866X-2021-29-s2-1350-1357

16. Xiao J, Cheung JK, et al. Temporal changes in factors associated with COVID-19 vaccine hesitancy and uptake among adults in Hong Kong: Serial cross-sectional surveys. Lancet Reg Health West Pac. 2022; 23: 100441. doi:10.1016/j.lanwpc.2022.100441

17. Zhidkova EA, Kostenko NA, Goryaev AA, Gurevich KG. Peculiarities of the incidence and course of COVID-19 among the employees of the CHUZ JSC «Russian Railways». Occupational Health and Industrial Ecology. 2021; 61:534–9. (In Russ). doi:10.31089/1026-9428-2021-61-8-534-539